Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H,
Peptide-based imaging agent developer Diatech of Londonderry, NH, has filed an investigationalnew drug (IND) application with the Food and Drug Administrationfor a new radiopharmaceutical that detects infections of unknownorigin. The agent, Tc-99m P483H, is a technetium-99m-labeled syntheticpeptide designed to home in on infection sites where white bloodcells are elevated as the body fights infection.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.